Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

Size Price Stock Quantity  
In DMSO USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 M3[zO2Z2dmO2aX;uJGF{e2G7 MkjoNE42yqEQvF2= MWCyOEBp M2TMOJdifGW{ NFPYSmRud2S3bHH0[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDNRWdGNUFibXXtZoVzew>? MUCyOVEzOzB6Mh?=
Eca109 NY[3NIVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nVWlAvPS9{LkWvOUDPxE1? NXzpemkxOjRxNEivO|IhcA>? Moj6e4F1\XJ? NHezTI5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NIDDUm8zPTF{M{C4Ni=>
Eca109 MmjaSpVv[3Srb36gRZN{[Xl? NYLMS|Y4OC53wrFOwG0> MWK2M|EzNzJ2IHi= Mlr5e4F1\XJ? NFzJcY5qdmirYnn0d{Bk\WyuIH3p[5JifGmxbtMg MX2yOVEzOzB6Mh?=
Eca109 NUHwXIVvTnWwY4Tpc44hSXO|YYm= NGC2c|UxNjYEoN88US=> M{j1U|I1KGh? M3TBcZdifGW{ NXjMZYpScW6qaXLpeJMh[2WubDDpcpZie2mxbh?= MoK5NlUyOjNyOEK=
Eca109 NYK4TWs5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzxc5oxNjYEoN88US=> Ml60NlQhcA>? MYD3ZZRmeg>? NV\K[m9VcW6mdXPld{BIOi:PIHHydoV{fCCrbjD0bIUh[2WubDDjfYNt\Q>? MV2yOVEzOzB6Mh?=
Eca109 NGjQcFBHfW6ldHnvckBCe3OjeR?= NF\Ic5UxNjVxMTFOwG0> MlzCNlQhcA>? NWL3OHpIf2G2ZYK= Ml\2[IVkemWjc3XzJIV5eHKnc4Ppc44hd2ZiTl[t{tpDOiCjbnSgUW1ROg>? NXnnbHpFOjVzMkOwPFI>
SW1116  M1vjcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHn2N2YxNjVxMT:yM|Uh|ryP MnLGOFghcA>? Mk\2SG1UVw>? M4DCSYVvcGGwY3XzJJRp\SCJZX\peIlvcWJiaX7keYNm\CClZXzsJIlvcGmkaYTpc44> M1zBZVI1QDd2Mki2
LOVO MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLaNXExNjVxMT:yM|Uh|ryP NGW0NWs1QCCq NWrJO4FyTE2VTx?= MYrlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u NITi[GIzPDh5NEK4Oi=>
SW1116  NV[2bnBxTnWwY4Tpc44hSXO|YYm= NXPaWod4OTBizszN Mn\WOFghcA>? NXnyT2pQTE2VTx?= NXrobVIzcW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk MV2yOFg4PDJ6Nh?=
LOVO NXLtXY9VTnWwY4Tpc44hSXO|YYm= NHTPcXcyOCEQvF2= Ml36OFghcA>? NWn5O5o5TE2VTx?= MV3pcoNz\WG|ZYOgeIhmKGWoZnXjeIl3\SCjdDDpcohq[mm2aX7nJGFMXCCjbnSgcXRQWiC|aXfuZYxqdmdicHH0bJdigXNiY3;tZolv\WRid3n0bEBo\W[rdHnubYI> NHPseIkzPDh5NEK4Oi=>
SW1116  NUjFR5EySXCxcITvd4l{KEG|c3H5 MkSwNVAh|ryP MXm0PEBp MV;EUXNQ MlnI[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz M4PWV|I1QDd2Mki2
LOVO MlrHRZBweHSxc3nzJGF{e2G7 NX;TcYNNOTBizszN M{XQclQ5KGh? MkX4SG1UVw>? Mnf5[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz MnywNlQ5PzR{OE[=
RPMI-8226 NEftUlhCeG:ydH;zbZMhSXO|YYm= MojQNU8zKM7:TR?= MkHFOFgwPzJxOU[gbC=> MUnEUXNQ MXLpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NFraZpMzPDh|M{GwPC=>
OPM-2  M4HXfWFxd3C2b4Ppd{BCe3OjeR?= NW\SbJA4OS9{IN88US=> Ml;DO|IwQTZxMUKwJIg> M3iyZmROW09? NX7EO4lWcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NHvTfGczPDh|M{GwPC=>
JJN3  NUG4WGxrSXCxcITvd4l{KEG|c3H5 MUWwMlUwOSEQvF2= NHTuRVQzPC92ODDo MYfEUXNQ MVLpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MnjsNlQ5OzNzMEi=
NCI-H929  MlnkRZBweHSxc3nzJGF{e2G7 NIP3TXAyNzJizszN NF7WXGc4Oi97Nj:xNlAhcA>? NGnDR5JFVVOR MYnpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M172clI1QDN|MUC4
RPMI-8226 M1nuR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nhbFEwOiEQvF2= MX6yOE81QC95MjDo M{HhVGROW09? NVfmVXBy[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= M2r0clI1QDN|MUC4
OPM-2  Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXWNU8zKM7:TR?= NFHvR|IzPC92OD:3NkBp MorXSG1UVw>? M4XmfIFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 MUGyOFg{OzFyOB?=
JJN3  NIHxOohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPZNE42NzFizszN NH7yV3UzPC92OD:3NkBp MXrEUXNQ MX7h[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? NF;FOowzPDh|M{GwPC=>
NCI-H929  M3f2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf6NHZSOS9{IN88US=> NWfsbmpqOjRxNEivO|IhcA>? MVPEUXNQ MlL1ZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? Ml\lNlQ5OzNzMEi=
HeLa NHzyR5hMcW6jc3WgRZN{[Xl? MYTLbV0yODBy4pETOVAxOCEQvF2g[o9zKGiHTmSx MUKyOFc5ODB7OB?=
HeLa M{nOTmtqdmG|ZTDBd5NigQ>? NVvY[5k5U2l;NT62JOKyKDBwNTFOwG0h\m:{IHjFUnQz MluwNlQ4QDByOUi=
HeLa MXTLbY5ie2ViQYPzZZk> NIHaZotMcT1{MT62JOKyKDNwMDFOwG0h\m:{IHjDUnQy NIPSSHEzPDd6MEC5PC=>
HeLa M{f6UGtqdmG|ZTDBd5NigQ>? NWnrXG9QU2l;MUSuOEDDuSB2Lk[g{txOKG[xcjDoR25VOw>? MUGyOFc5ODB7OB?=
NB4 NGGy[2JHfW6ldHnvckBCe3OjeR?= NETGPWYzNjVxNT:3MlUwOTBizszN Moe4NlQhcA>? NGjX[W1FVVOR M1:xUolv[3KnYYPlZUB1cGViZYjwdoV{e2mxbjDv[kBxemWldYLzc5IhdWmULUGyOYE> M1nxRlI1PDh2OEew
CD4+ CD25− T  MmLRSpVv[3Srb36gRZN{[Xl? MX2xM|Uh|ryP NIL1Z|Bz\WS3Y3XTJIdtd2KjbDDEUmEhdWW2aInsZZRqd25? MmDWNlQ1PzZ|NkC=
BV-173 NWPU[FZCSXCxcITvd4l{KEG|c3H5 NFnrWVMxNjJ3L{CuOU8xNjd3L{Gg{txO NVvBXZJUPDhxN{KvPVYhcA>? M3XFNuKhWEKV MXnpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= NUTrRXd2OjR2MkO2NVM>
ML-1 MUjBdI9xfG:|aYOgRZN{[Xl? NGLpc4MxNjJ3L{CuOU8xNjd3L{Gg{txO MkPZOFgwPzJxOU[gbC=> MWlCpHBDWw>? NFrWSnJqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> M1vSVVI1PDJ|NkGz
HL-60 Ml\ORZBweHSxc3nzJGF{e2G7 NYLIb4NGOC5{NT:wMlUwOC55NT:xJO69VQ>? MWC0PE84Oi97NjDo NWT4SplqyqCSQmO= NFvHenBqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> MmDKNlQ1OjN4MUO=
KG-1a MX\BdI9xfG:|aYOgRZN{[Xl? MX2wMlI2NzBwNT:wMlc2NzFizszN Mo\jOFgwPzJxOU[gbC=> NXXGfXdOyqCSQmO= MYLpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= M3XhZlI1PDJ|NkGz
BV-173 MmjqSpVv[3Srb36gRZN{[Xl? NHTzV3QzPTBxNUCwcm0> Mn3kOFghcA>? NEG4UXjDqFCEUx?= NI\i[5ZqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= MkX1NlQ1OjN4MUO=
CEM MkjlSpVv[3Srb36gRZN{[Xl? NX3pZolDOjVyL{WwNI5O Mnr4OFghcA>? MoHNxsBRSlN? NV;FTVlrcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl Mn7SNlQ1OjN4MUO=
HL-60 M2HadmZ2dmO2aX;uJGF{e2G7 NGm5e|czPTBxNUCwcm0> M2q0XlQ5KGh? M1rWTeKhWEKV NYe3RVNPcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl MUmyOFQzOzZzMx?=
ML-1 MV;GeY5kfGmxbjDBd5NigQ>? MUOyOVAwPTBybl2= NUPjVYxxPDhiaB?= M3XIbeKhWEKV Mkm0bY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MmDlNlQ1OjN4MUO=
DLD-1 MVrGeY5kfGmxbjDBd5NigQ>? MWWyOVAwPTBybl2= Mnf5OFghcA>? NXPSOY01yqCSQmO= M{f4N4RwKG6xdDDpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? MUSyOFQzOzZzMx?=
HCT-116 MmHtSpVv[3Srb36gRZN{[Xl? NXmw[JA1OjVyL{WwNI5O NH\sdpQ1QCCq NF3sVlLDqFCEUx?= MXPkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm NF[wbI0zPDR{M{[xNy=>
U937-A/E-9/14/18  MkPRRZBweHSxc3nzJGF{e2G7 NF;UUI0xNjBzL{CuNU8yNzFyIN88US=> MXW0PEBp NGHSfIJqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MWeyOFMxODR3Nh?=
HT29 MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXu3NkBp NH\3RYZKSzVyPUG0NFDDuTF5OTFOwG0> MYCyOFE4OjB4MR?=
SW48 NX3iWFhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTvO|IhcA>? MVvJR|UxRTF3LkNCtVYvOiEQvF2= MlXjNlQyPzJyNkG=
HCT116 NHjI[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjtN2FNPzJiaB?= Moq5TWM2OD1zLkhCtVAvPCEQvF2= MljQNlQyPzJyNkG=
HepG2 NGWze4dHfW6ldHnvckBCe3OjeR?= MonXNE42NzFizszN M3fPTFI1KGh? MYPEUXNQ NX\j[JFKfXBvcnXneYxifGWmIITo[UBz\WyjdHn2[UBQS1SQMjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= NYPTV|ZpOjRzNE[4O|Q>
LS174T MoLrSpVv[3Srb36gRZN{[Xl? NXzaUVI4OC53L{Gg{txO NXrrdpZIOjRiaB?= MYXEUXNQ M3fRNoxm[WRidH:gZY4hcW6lcnXhd4Uhd2ZiT1PUUlIhdGW4ZXzz NISwXYgzPDF2Nki3OC=>
HepG2 Ml\yRZBweHSxc3nzJGF{e2G7 NG\CTXYyNzFyL{GwNEDPxE1? NXvUWJhWPyCm NHXyVnNFVVOR MkHMbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mnn2NlQyPDZ6N{S=
LS174T MmK2RZBweHSxc3nzJGF{e2G7 MWqxM|ExNzFyMDFOwG0> NH3XOVQ4KGR? MY\EUXNQ MkO0bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NGnmWVIzPDF2Nki3OC=>
QBC-939 NXfhdGxzSXCxcITvd4l{KEG|c3H5 NFjOO4IyNzFyL{GwNEDPxE1? MYS3JIQ> NXz4dY1TTE2VTx?= M1jCV4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NILwU5QzPDF2Nki3OC=>
U251 NW\qU|M6SXCxcITvd4l{KEG|c3H5 M2XMUFEwOTBxMUCwJO69VQ>? MoPjO{Bl MVnEUXNQ MVvpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1jNeVI1OTR4OEe0
HL-60 NUj0XnlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGxJO69VQ>? NUPv[HQ1PDhiaB?= NGjQUnFqdmO{ZXHz[ZMhTzJvcHjhd4Uh[2WubDDmdoFkfGmxbh?= NX:5dIJDOjRyMECzNlQ>
MDA‑MB‑453 M3rYOGZ2dmO2aX;uJGF{e2G7 NHXlXJcxNjJxMTFOwG0> NVTZdYZwPzJiaB?= Ml34Z4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg NEXGNHkzOzh2NEKyPC=>
HCC1569 MYTGeY5kfGmxbjDBd5NigQ>? MnrYNE4zNzFizszN NVLscoxWPzJiaB?= MVPjZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= MljMNlM5PDR{Mki=
BT‑474 NUjNXoJKTnWwY4Tpc44hSXO|YYm= MWSwMlIwOSEQvF2= NVHkblc4PzJiaB?= MW\jZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= MXGyN|g1PDJ{OB?=
AGS M{DSWWFxd3C2b4Ppd{BCe3OjeR?= NFrUWpA2NzFyL{KwM|UxKM7:TR?= NVO3e|UzPDkEoHlCpC=> NXnWZ205TE2VTx?= MnHobY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA> NGL4NJYzOzV6Mke4OC=>
A549 MV3BdI9xfG:|aYOgRZN{[Xl? NFXacGw2NzFyL{KwM|UxKM7:TR?= MUW0POKhcMLi MYfEUXNQ MVfpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=> NHHsU3MzOzV6Mke4OC=>
AGS  NYn2PIlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVG1M|ExNzJyL{WwJO69VQ>? NELWVXY1QMLiaNMg M4LLTWROW09? NEfMWGRqdmS3Y3XzJGczN01icHjhd4Uh[XK{ZYP0xsA> NVXNVWg5OjN3OEK3PFQ>
Kasumi-1 MnXFRZBweHSxc3nzJGF{e2G7 MYmwMlUh|ryP NHPJSnM1QMLiaNMg NE\FdXJl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> MmXMNlM1QTN|NEi=
OCI-AML3 MlTmRZBweHSxc3nzJGF{e2G7 M1LmSFIvPSEQvF2= NEXDcFQ1QMLiaNMg NInCbXdl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> MYGyN|Q6OzN2OB?=
MV4-11 M37VdGFxd3C2b4Ppd{BCe3OjeR?= NXvzfIJTOi53IN88US=> M4PhVlQ5yqCqwrC= MmrU[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= NIqxeIMzOzR7M{O0PC=>
NK  M1uwSGN6fG:2b4jpeJkhSXO|YYm= MnTrNE4xOi1{MDFOwG0> M1PJR|Uh\A>? MU\k[YNz\WG|ZYOgeIhmKGO7dH;sfZRq[yCjY4Tpeol1gSCxZjDOT{Bk\WyuczDheEBqdnSncn3l[IlifGViY3;uZ4VvfHKjdHnvcpMhemW|dXz0bY5oKGmwIHGgWU1{cGGyZXSg[I9{\eLCk4Lld5BwdnOnIHP1dpZm NHO3T|kzOzN{OEC4PC=>
NK  MknlRZBweHSxc3nzJGF{e2G7 NXXxPGd5OC5yMj2yNEDPxE1? NWXuV3F5PSCm NHnBTWll\WO{ZXHz[UBPUyClZXzsJJBzd2yrZnXyZZRqd25iYX7kJJZq[WKrbHn0fUBieyC2aHWgZ49v[2WwdILheIlwdiCrbnPy[YF{\WR? MkPpNlM{OjhyOEi=
NK  M3PGOGZ2dmO2aX;uJGF{e2G7 M2njflAvODFvMkCg{txO Mlz1OUBl MkLkZ4F2e2W|IHj5dI9u\XSqeXzheIlwdiCxZjDOT{Bk\WyuczDpckBiKGSxc3ZihLNz\XOyb37z[S=> MXyyN|MzQDB6OB?=
MOLT4/DNR Mmi2SpVv[3Srb36gRZN{[Xl? NESyd3E2KM7:TR?= M{jSO|Qh\A>? NHHEc4tz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? M1PScVI{ODZyNUew
Jurkat/DOX NETUVlFHfW6ldHnvckBCe3OjeR?= MlnkOUDPxE1? MlT4OEBl M1vLO5Jm\HWlZYOgRWJESjFibWLORUBmgHC{ZYPzbY9v M2XyWVI{ODZyNUew
MOLT4/DNR Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rsc|Uh|ryP MUK0JIQ> MVry[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 MmnPNlMxPjB3N{C=
Jurkat/DOX M1fBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfpSmJCPSEQvF2= NV3HTVV3PCCm NG\lc3lz\WS3Y3XzJJRp\SCLQ{WwxsB3[Wy3ZTDmc5Ih\GG3bn;yeYJq[2mwIIPlcpNqfGm4aYT5 MYKyN|A3ODV5MB?=
ccRCC  MWHBdI9xfG:|aYOgRZN{[Xl? MkHiNE4xOS1zMN88US=> M13sV|czKGh? NHr5bZlFVVOR NFnoSGZp[XNibXnubY1idCCnZn\lZ5Qhd25iY3XscEBxem:uaX\ldoF1cW:w MmnjNlI5OjZ2Nke=
TNBC  NUCzdFl7SXCxcITvd4l{KEG|c3H5 M3O1SlAvODFvMUFOwG0> MXS3NkBp MnK3SG1UVw>? M4DXTYhieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25? MVOyNlgzPjR4Nx?=
A498 MY\BdI9xfG:|aYOgRZN{[Xl? NXPhbGpJOC5yMT2xNO69VQ>? M{fQXFczKGh? M4T4VWROW09? NEnhVXRqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv NGf6b48zOjh{NkS2Oy=>
KIJ265T MoLYRZBweHSxc3nzJGF{e2G7 MkDYNE4xOS1zMN88US=> NWTVSJhWPzJiaB?= MVjEUXNQ NXLvdlI6cW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? NWSwWYc5OjJ6Mk[0Olc>
MDA-231 MUDBdI9xfG:|aYOgRZN{[Xl? MW[wMlAyNTFyzszN Mk\SO|IhcA>? NInxcYFFVVOR NFm1SItqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv NV[xNnhqOjJ6Mk[0Olc>
BT-20 MnWzRZBweHSxc3nzJGF{e2G7 NETYN4wxNjBzLUGw{txO MU[3NkBp MXXEUXNQ MYjpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu Mkm3NlI5OjZ2Nke=
U937 MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX21MVIxKM7:TR?= NEjQWFMzPC92OD:3NkBp NH3QSXNqdmS3Y3XzJIEh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz NUXyfIFXOjJ5NkewNlE>
HL60 NFvE[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInR[JM2NTJyIN88US=> MmfnNlQwPDhxN{KgbC=> NUHIUJdJcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NI\neZAzOjd4N{CyNS=>
U937 NE[1cIlCeG:ydH;zbZMhSXO|YYm= M33kT|E2KM7:TR?= Mmq4NlQwPDhxN{KgbC=> MWTpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NGnubIMzOjd4N{CyNS=>
HL60 M{LBT2Fxd3C2b4Ppd{BCe3OjeR?= NH3Z[oIyPSEQvF2= NH7rcowzPC92OD:3NkBp M{nxS4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MnTYNlI4PjdyMkG=
LS411N  M{nEcmFxd3C2b4Ppd{BCe3OjeR?= NX6wWXFDOC53IN88US=> NGTTfXI4OiCq M{\1c4lv[3KnYYPld{BH[XNibWLORUBt\X[nbB?= M3SyUFIzPDZzNkm1
MDA-MB-231 NFriZXlCeG:ydH;zbZMhSXO|YYm= M{fPPVExKM7:TR?= MlXPOFghcA>? M4r3cpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mo\tNlE5QDd4OUe=
MCF-7  NX65[HNLSXCxcITvd4l{KEG|c3H5 M1y4TVExKM7:TR?= NUXuXphEPDhiaB?= NEHScnZz\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NYHKTIdVOjF6OEe2PVc>
A375 NUDZOZU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTyNE42KM7:TR?= MljRNU82NzhiZB?= MX;pcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? MW[yNVc6PjZ{Mh?=
SKMEL1 NX\xUG5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TJelAvPSEQvF2= M4P4clEwPS96IHS= MVnpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? M2XETFIyPzl4NkKy
SKMEL3 M3rXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrBO25DOC53IN88US=> M32zTVEwPS96IHS= NF60XW5qdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= M{nR[|IyPzl4NkKy
SKMEL28 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFy5NWgxNjVizszN NH:3WlgyNzVxODDk NX7QXIx1cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NXTZdFd2OjF5OU[2NlI>
MeWo MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzaVIFtOC53IN88US=> MWexM|UwQCCm M3jtbIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NEixb2gzOTd7Nk[yNi=>
B16 M{X0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfJdYxHOC53IN88US=> MknPNU82NzhiZB?= M3Ww[4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| MnTENlE4QTZ4MkK=
Ly 1 Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[4e2tYOjRiaB?= NEXXSnRKSzVyPUeuN{DPxE1? NVi5bG9jOjF5N{KwOFk>
Ly 7 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnf3NlQhcA>? M1PmS2lEPTB;MUCuO{DPxE1? NHrjcJIzOTd5MkC0PS=>
Su-DHL6 NWPCbIg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;yNlQhcA>? M4HEdmlEPTExvK6yNEDPxE1? M3[2PVIyPzd{MES5
Ly 10 MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLJ[5YzPCCq NVfheYRmUUN3MP-8olIxKM7:TR?= MmfyNlE4PzJyNEm=
RIVA NXLDcGhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TxV|I1KGh? NVH4fWljUUN3MP-8olIxKM7:TR?= NHjKVHozOTd5MkC0PS=>
Su-DHL2 NVLCeGdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDhNlQhcA>? MYLJR|Ux97zgMkCg{txO MlTlNlE4PzJyNEm=
Ly 1 NHfLUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXO0PEBp NFX2OZlKSzVyPUCuN|Qh|ryP MkjsNlE4PzJyNEm=
Ly 7 M2PqUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DGflQ5KGh? MnHFTWM2OD1yLkCyOUDPxE1? MojmNlE4PzJyNEm=
Su-DHL6 MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LYUVQ5KGh? M4PwNWlEPTExvK6yNEDPxE1? MmDGNlE4PzJyNEm=
Ly 10 NYHGUpBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHHOFghcA>? MkXvTWM2OD1zLkig{txO MYCyNVc4OjB2OR?=
RIVA M3jzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnrbZA1QCCq M{DGd2lEPTExvK6yNEDPxE1? M2LqV|IyPzd{MES5
Su-DHL2 M132S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDjWGlRPDhiaB?= MXfJR|UxRTF5LkSg{txO M{O2XlIyPzd{MES5
Ly 1 MkfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jwNVczKGh? MV;JR|UxRTBwMEGg{txO NHTyZZgzOTd5MkC0PS=>
Ly 7 M1u1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX23NkBp NVLhXWVSUUN3ME2wMlAyQCEQvF2= Mn;ONlE4PzJyNEm=
Su-DHL6 NH\leItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmG0O|IhcA>? MULJR|UxRTFwNjFOwG0> M1rEV|IyPzd{MES5
Ly 10 M3nITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIS2OIE4OiCq MoO2TWM2OD1zLkKg{txO M37jTFIyPzd{MES5
RIVA MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXS3NkBp NFTqOVhKSzVy78{eNlAh|ryP NEfNe3ozOTd5MkC0PS=>
Su-DHL2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWexOo03PzJiaB?= NU\hN444UUN3ME2xNU4zKM7:TR?= NIXXOWszOTd5MkC0PS=>

... Click to View More Cell Line Experimental Data

In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
+ Expand

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
+ Expand
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Formulation: Decitabine is dissolved in sterile PBS .
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol slightly soluble or insoluble
In vivo Add solvents individually and in order:
30% propylene glycol, 5% Tween 80, 65% D5W
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
Synonyms Deoxycytidine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT01479348 Enrolling by invitation Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 28, 2011 Early Phase 1
NCT03041688 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|TP53 wt Allele|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) October 2017 Phase 1
NCT03009240 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 1
NCT02890329 Not yet recruiting Chimerism|Hematopoietic Cell Transplantation Recipient|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) April 2017 Phase 1
NCT02847000 Not yet recruiting Metastatic Pancreatic Adenocarcinoma Yogen Saunthararajah|Case Comprehensive Cancer Center March 2017 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID